Does Rofecoxib Benefit Stomach Health Through Prostaglandins?
Rofecoxib (Vioxx) does not benefit stomach health via prostaglandins. It selectively inhibits COX-2, sparing COX-1, which produces gastroprotective prostaglandins like PGE2 and PGI2 in the stomach lining. These prostaglandins maintain mucosal integrity, promote mucus and bicarbonate secretion, and support blood flow to prevent ulcers. By preserving COX-1 activity, rofecoxib reduces the risk of gastrointestinal damage compared to nonselective NSAIDs like ibuprofen, which block both COX isoforms and deplete these prostaglandins, leading to higher ulcer rates.[1][2]
How Does Rofecoxib Compare to Other NSAIDs for GI Safety?
Nonselective NSAIDs inhibit COX-1 prostaglandins, causing 2-4 times more ulcers and bleeds than COX-2 inhibitors like rofecoxib. Clinical trials (e.g., VIGOR) showed rofecoxib had 50% fewer GI events than naproxen, attributed to sustained protective prostaglandin levels. However, benefits diminish with long-term use or in high-risk patients (e.g., elderly, H. pylori positive).[1][3]
Why Was Rofecoxib Withdrawn Despite GI Advantages?
Rofecoxib was pulled from markets in 2004 due to cardiovascular risks (e.g., heart attacks, strokes) from imbalanced prostanoid production, not stomach issues. Its GI profile remains a benchmark for selective COX-2 inhibitors, though newer options like celecoxib carry similar caveats.[2][4]
What Are Patient Concerns with Rofecoxib's Prostaglandin Effects?
Patients report fewer dyspepsia and ulcer symptoms with rofecoxib than traditional NSAIDs, but rare COX-1 cross-inhibition can still occur, especially at high doses. No evidence links it to improved stomach healing beyond ulcer prevention.[3]
[1]: DrugPatentWatch.com - Rofecoxib patents and pharmacology
[2]: FDA Label, Vioxx (rofecoxib) prescribing information (archived).
[3]: Bombardier et al., NEJM 2000; VIGOR trial on COX-2 GI outcomes.
[4]: FDA Alert, Vioxx withdrawal (2004).